Permission to Collect Blood Over Time for Research

Predicting DVT Risk in GI Cancer Patients Using Plasma Biomarkers

Status

Terminated

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00767234

Enrollment

104

Registered

2008-10-07

Start date

2008-08-31

Completion date

2011-10-31

Last updated

2016-07-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anal Cancer, Bile Duct Carcinoma, Carcinoma of the Large Intestine, Colon Rectal Cancer Adenocarcinoma, Esophageal Cancer, Gall Bladder Cancer, Gallbladder Carcinoma, Gastric (Stomach) Cancer, Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumor (GIST), Gastrooesophageal Cancer, Hepatobiliary Neoplasm, Liver Carcinoma, Pancreatic Cancer

Brief summary

To determine whether biomarkers assessed in blood samples can be used to detect individuals at risk for developing blood clots or worsening of their underlying disease. The ultimate goal of the study is to identify key biomarkers derived from blood that are most characteristic and informative of individuals who will go on to develop a clotting complication.

Interventions

PROCEDUREObservation

Standard of Care

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Male or female, \>= 18 years old. There are no ethnic restrictions. * Active cancers of the GI tract (gastroesophageal, colorectal, or pancreatic-biliary) that have completed TNM staging by the American Joint Committee on Cancer; stage III disease if diagnosed within 2 months and all stage IV disease * Ability to understand and the willingness to sign a written informed consent document. * Existing staging CT imaging study

Exclusion criteria

* Life expectancy \< 6 months * History of deep vein thrombosis (DVT) or pulmonary embolism (PE) * Known pregnancy or positive urine pregnancy test in pre-menopausal women * On anticoagulant therapy (heparin, warfarin, direct thrombin inhibitors) * No CT imaging studies, or contraindications to undergoing CT imaging * Existing or anticipated need for a tunneled central venous catheter * Clinic visitation to Stanford Cancer center for secondary consultation purposes only * Inability to give informed consent

Design outcomes

Primary

Measure	Time frame
Identify Biomarkers	3 years

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026